Exercise Molecule L‑BAIBA Drives Muscle Remodelling and Boosts Endurance
The study identifies a PGC1α–BAIBA–PPARδ signalling pathway that could be targeted to protect muscle in type 2 diabetes pending human trials.
Overview
- The University of Leeds‑led paper, which was published on 18 August 2026, reports that the exercise‑linked metabolite L‑β‑aminoisobutyric acid (L‑BAIBA) acts as a signal that changes how muscle adapts.
- The team found that the L‑enantiomer of BAIBA is the active form and that it works through a PGC1α–BAIBA–PPARδ axis to increase mitochondrial content and contractile function in muscle.
- In mice, giving BAIBA in drinking water both mimicked the effects of aerobic training and increased the benefits of voluntary exercise, improving running endurance and muscle performance.
- Human plasma measurements showed that circulating L‑BAIBA levels correlate with aerobic fitness, but those data are associative and do not prove that supplementation will help people.
- The findings point to therapeutic potential for diabetes‑related muscle weakness, yet the work is preclinical only, BAIBA is already sold as a supplement without proven clinical benefit, and randomized human trials and safety testing are needed.